Immuneering’s Drug Adds 9 Quality Months in Pancreatic Cancer

Immuneering's Atebimetinib Shows 17.3 Months MOS in Pancreatic Cancer Phase 2a

Immuneering's investigational drug, atebimetinib, in combination with modified gemcitabine/nab-paclitaxel (mGnP), demonstrated a median overall survival (MOS) of 17.3 months in a Phase 2a trial for 55 patients with first-line metastatic pancreatic cancer. This outcome significantly surpasses the 8.5 months MOS observed with standard of care gemcitabine/nab-paclitaxel (GnP) in the pivotal Phase 3 MPACT study. The trial also reported a median progression-free survival of 8.3 months, an 82% disease control rate, and a 36% confirmed overall response rate. Immuneering highlighted the robust tolerability profile of the combination, which is considered crucial for patient quality of life and sustained treatment. These positive results were elaborated in an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting.

• Immuneering's atebimetinib, combined with modified gemcitabine/nab-paclitaxel, achieved a median overall survival of 17.3 months in 55 patients with first-line metastatic pancreatic cancer. This represents a substantial improvement of nearly nine months compared to the 8.5 months MOS observed with standard of care GnP, establishing a compelling new benchmark for survival in this difficult-to-treat disease.
• A key finding was the robust tolerability profile of the atebimetinib combination, with only two categories of Grade 3 or higher treatment-related adverse events affecting at least 10% of participants, both linked to chemotherapy. This improved tolerability is critical for patient quality of life, enabling longer treatment adherence, and potentially increasing the likelihood of patients being able to receive subsequent lines of therapy, factors directly linked to overall survival.
• Following these positive Phase 2a results, Immuneering plans to advance atebimetinib into a pivotal Phase 3 MAPKeeper 301 trial, aiming to enroll approximately 510 patients around mid-year, with topline results anticipated in mid-2028. The company positions its first-line treatment as complementary to emerging second-line RAS inhibitors, suggesting a comprehensive approach to pancreatic cancer treatment.

Atebimetinib's Phase 2a Data: Extending Survival with Robust Tolerability

Recent clinical trials in metastatic pancreatic cancer have explored novel therapeutic combinations and optimized dosing regimens across multiple treatment lines. These studies demonstrate incremental improvements in survival outcomes while highlighting the continued challenge of managing treatment-related toxicities in this aggressive malignancy.

• NALIRIFOX vs. nal-IRI/FL (2026): Second-line NALIRIFOX (nanoliposomal irinotecan plus oxaliplatin, fluorouracil, and leucovorin) showed superior median PFS of 4.0 months versus 2.5 months for nal-IRI/FL (HR: 0.686; p=0.021), though median OS remained similar at 7.0 versus 6.3 months. Grade 3-4 adverse events included febrile neutropenia, neutropenia, thrombocytopenia, and peripheral neuropathy, but were generally transient and manageable.

• TCOG T5217 Trial (2026): Randomized phase II study comparing SLOG (S-1/leucovorin plus oxaliplatin and gemcitabine) versus mFOLFIRINOX as first-line therapy in 129 patients found no significant difference in median PFS (7.5 vs. 6.5 months; p=0.88) or median OS (12.9 vs. 12.1 months). SLOG demonstrated significantly less grade 3/4 neutropenia (15.4% vs. 53.1%; p<0.001) but more non-hematological toxicities.

• Setidegrasib Phase 1 Study (2026): The KRAS G12D-targeted protein degrader achieved a 24% response rate in 21 metastatic pancreatic cancer patients receiving the 600-mg dose as second- or third-line treatment, with median PFS of 3.0 months and median OS of 10.3 months. Most common adverse events were transient infusion-related reactions (80%) and nausea (30%), with grade 3 or higher events in 42% of patients.

• LEAP-005 Study (2026): Lenvatinib plus pembrolizumab combination in previously treated advanced pancreatic cancer (cohort G, n=103) demonstrated modest activity with an objective response rate of 7.8% and manageable safety profile, though grade 3-4 treatment-related adverse events occurred in 59.2% of participants.

• Japanese Phase II/III Trial (2025): This large randomized study of 527 patients comparing mFOLFIRINOX, S-IROX, and nab-paclitaxel plus gemcitabine was terminated for futility, with nab-paclitaxel plus gemcitabine showing superior median OS (17.1 months) compared to mFOLFIRINOX (14.0 months) and S-IROX (13.6 months). Grade 3-4 anorexia was more frequent with the FOLFIRINOX-based regimens.

Redefining Trade-offs: Atebimetinib's Place in Pancreatic Cancer Treatment

Recent comparative studies demonstrate that investigational therapies for metastatic pancreatic cancer have largely failed to surpass established standard-of-care treatments. The most recent trials from 2023-2026 show that novel combination regimens like SOXIRI (S-1/oxaliplatin/irinotecan) and SLOG (S-1/leucovorin plus oxaliplatin and gemcitabine) achieved non-inferiority but not superiority compared to modified FOLFIRINOX. SOXIRI showed comparable overall survival (12.1 vs. 11.2 months, HR=1.04, p=0.81) and progression-free survival (6.5 vs. 6.8 months) to mFOLFIRINOX, while SLOG demonstrated similar efficacy with median progression-free survival of 7.5 versus 6.5 months (p=0.88) and overall survival of 12.9 versus 12.1 months. Notably, SLOG offered a more favorable toxicity profile with significantly reduced grade 3/4 neutropenia (15.4% vs. 53.1%; p<0.001), though this came at the cost of increased non-hematological toxicities.

Real-world evidence from large cohort studies confirms the equipoise between current standard regimens, with nab-paclitaxel plus gemcitabine and FOLFIRINOX showing virtually identical survival outcomes. A 2019 study of 654 patients demonstrated median overall survival of 12.1 months for nab-paclitaxel plus gemcitabine versus 13.8 months for FOLFIRINOX (HR=0.99, P=0.96), with comparable efficacy maintained across performance status subgroups and second-line therapy recipients. The primary differentiator remains the toxicity profile, with nab-paclitaxel plus gemcitabine associated with significantly lower rates of diarrhea, fatigue, mucositis, and gastrointestinal adverse events compared to FOLFIRINOX.

Emerging therapeutic approaches show promise but remain investigational. Immunotherapy combinations have demonstrated modest benefits in selected populations, though immune checkpoint inhibitors combined with radiotherapy showed concerning mortality signals (HR = 1.18; 95% CI: 1.04-1.34). Biomarker-driven strategies are yielding more encouraging results, with patients harboring homologous recombination deficiency mutations showing significantly longer median progression-free survival (11.9 vs. 7.0 months; p=0.008) and overall survival (17.7 vs. 11.7 months; p=0.036). Drug repurposing studies indicate that concomitant use of angiotensin receptor blockers with standard chemotherapy may extend median overall survival to 8.9 months, suggesting potential for optimization of existing regimens rather than wholesale replacement.

Mapping the Future: The MAPKeeper 301 Phase 3 Trial

The clinical trial landscape for metastatic pancreatic cancer encompasses diverse study designs ranging from phase 2 single-arm studies to large phase 3 randomized controlled trials. These trials have evaluated various therapeutic approaches including targeted agents, immunotherapies, and combination regimens, with overall survival serving as the predominant primary endpoint across most studies.

A New Benchmark for First-Line Metastatic Pancreatic Cancer

Pancreatic cancer remains a formidable challenge in oncology, notorious for its aggressive nature and exceptionally poor prognosis. For decades, progress in extending the lives of patients with metastatic disease has been incremental, with median overall survival (OS) often hovering in the single-digit months. Standard first-line regimens like gemcitabine/nab-paclitaxel (GnP) typically offer an OS of around 8.5 months, while more intensive combinations such as FOLFIRINOX push this to approximately 10-11 months. This context underscores the profound significance of Immuneering's recent Phase 2a data for atebimetinib combined with modified gemcitabine/nab-paclitaxel (mGnP).

The reported median OS of 17.3 months in 55 patients with first-line metastatic pancreatic cancer is a striking figure, nearly doubling the historical 8.5 months seen with standard GnP. This level of improvement, if validated, could fundamentally redefine expectations for treatment outcomes in this devastating disease. Such robust efficacy, coupled with a highlighted 'robust tolerability' profile, is critical for a patient population where quality of life is paramount.

However, the path forward is not without its considerations. These compelling results originate from a relatively small Phase 2a study; larger, randomized Phase 3 trials are necessary to confirm efficacy and fully characterize the safety profile. While the comparison to GnP is impressive, future studies will need to position atebimetinib + mGnP against other effective first-line regimens like FOLFIRINOX. Demonstrating superiority or a more favorable risk-benefit profile against these alternatives will be crucial for widespread adoption. A comprehensive understanding of the long-term safety and specific adverse event rates will also be vital, as maintaining tolerability is key to sustained treatment.

Should these promising early signals translate into definitive Phase 3 success, atebimetinib + mGnP could emerge as a new benchmark, offering a much-needed beacon of hope and a substantial extension of life for patients battling metastatic pancreatic cancer. This would represent a pivotal moment in the fight against one of oncology's most challenging adversaries.